Tesamorelin

Yes, as Egrifta, but only for a specific approved indication: excess abdominal fat in HIV-associated lipodystrophy. Research-labeled tesamorelin is not that approved product.

Broader growth-hormone-axis and visceral fat research, though those uses fall outside its approved indication.

Yes, as a growth-hormone-releasing factor it falls under WADA's prohibited list.

It can genuinely help, but it's worth being precise about what it actually targets. Tesamorelin's clinical evidence is specifically for visceral fat — the deep fat packed around your organs, not the layer just under your skin that you can pinch.

The path there: it supports your body's own GH levels through endogenous release, which over time is associated with real improvements in body composition. Some people also report better sleep and recovery alongside it, but that's anecdotal, not something the clinical trials actually measured — the trials looked at trunk fat specifically, not general weight loss or the softer belly fat sitting under the skin.

The biggest difference is the paper trail: Tesamorelin has actual FDA approval and clinical trial data behind it, while CJC-1295 + Ipamorelin is the more commonly run community stack, but with far less formal human data. Dosing differs too — Tesamorelin is typically once a day, while CJC-1295 + Ipamorelin usually runs once or twice daily.

Different approach entirely. Tesamorelin nudges your own body into producing more growth hormone; HGH is the growth hormone itself, injected directly. That directness makes HGH more potent, but also more expensive and higher-risk. Tesamorelin is more targeted and generally gentler than direct HGH, though it still calls for the same kind of monitoring.

Both work the same way — they're both GHRH analogs stimulating your body's own GH release. The real difference is track record: Tesamorelin carries more clinical data and FDA recognition, while Sermorelin has simply been around longer in wellness-clinic settings.

Not fast, and it's worth setting expectations accordingly. Visceral fat changes are typically assessed over 12 weeks or longer in the actual research — this isn't a compound where you'll see something dramatic in the first couple of weeks.

There's something to it, though Tesamorelin is actually in the better-positioned group here. It's short-acting — clearing your system in minutes rather than lingering for days — which gives your pituitary real recovery time between pulses, the same pattern that makes Sermorelin more forgiving with continuous use than something like CJC-1295 with DAC. That said, cycling (commonly cited: roughly 8-12 weeks on, then a break) is still standard practice as a precaution.

Legally, yes it matters — Tesamorelin is fully FDA-approved, but only for one specific thing: reducing visceral fat in HIV-associated lipodystrophy, marketed as Egrifta. There's no approved indication for general belly fat, bodybuilding, or anti-aging. Doctors can legally prescribe an approved drug off-label at their discretion, and that does happen — but off-label use for general fat loss is extrapolated from the HIV data, not backed by its own registration-quality trials. The FDA approval gives it real credibility as a compound, but doesn't guarantee it works the same way for a different population.

Yes, noticeably. Research-chemical pricing runs roughly $30-80 per vial, but through telehealth/clinic channels it runs $200-400 a month, up to $1,500 from premium providers — compared to Sermorelin or CJC-1295+Ipamorelin, typically under $200 a cycle through similar channels. The premium tracks directly with it being the only GHRH analog with actual FDA-validated trial data behind it.

There's a real basis for it — like the other GHRH analogs, it can support the deep, slow-wave sleep stage tied to natural GH release. Interestingly, difficulty sleeping shows up in the clinical trial data too, just less frequently than joint pain or injection-site reactions — both directions are reported, and where you land probably comes down to individual response and dose timing.

Yes, and it's actually one of the more common reported effects — fluid retention (edema) showed up in 11% of clinical trial participants, and the FDA's own label specifically warns about it, alongside joint pain and carpal tunnel syndrome. The reassuring part: trial data shows these effects were mostly mild-to-moderate and dropped off significantly after the first 12 weeks.

Yes, one of the most commonly reported ones — joint pain (arthralgia) occurred in 15% of clinical trial participants, sometimes alongside general stiffness or aches in the arms and legs. Same pattern as bloating: mostly mild-to-moderate, easing up substantially after the first 12 weeks. Across the actual trials, fewer than 3% stopped treatment because of these effects.